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Abstract
Background: Hepatitis C virus (HCV) infection is a widespread problem in prisons. The present study aimed to assess
the prevalence of HCV seropositivity, HCV genotypes, factors associated with HCV seropositivity in newly incarcerated
prisoners and to report experiences of treatment with pegylated interferon/ribavirin for HCV-positive inmates.
Methods: Patient data were extracted from the Estonian prison medical information system (Vanglate meditsiiniline
infosüsteem) databases.
Results: Among 1845 prisoners newly incarcerated from January 2014 to January 2015, the overall prevalence of HCV
was 56.3% (95% CI: 54 to 59), and 25.5% (95% CI: 23.5 to 27.6%) had HIV (39.0% had neither). The all-inclusive HCV
testing strategy identified 37.7% more HCV infected prisoners than the risk-based (drug use history, HIV status) case
finding. Factors associated with HCV seropositivity included history of drug use (aOR 6.51 95%CI 5.12–8.28), HIV co-
infection (aOR 2.56 95%CI 1.92–3.43), previous incarceration (aOR 3.61 95%CI 2.48–4.04), and increasing age. The main
HCV genotypes were 3a (n = 172, 44.4%) and 1b (n = 135, 35.2%). Twenty-five prisoners received HCV treatment: 60%
(n = 15) were cured, 16% (n = 4) relapsed (3 with genotype 3a, one with 1b), and 12% (n = 3) were unresponsive (all
with genotype 3a).
Conclusions: HCV seropositivity rate is high and HCV tretment rate is very low in Estonian prisons. Optimizing
case finding and scaling up treatment is critical to addressing the health needs of prisoners and meeting public
health goals.
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Background
Hepatitis C virus (HCV) infection is an escalating global
health issue and prisoners are emerging as an important
high-risk group. HCV prevalence in this subpopulation
ranges from 3 to 38% [1, 2]. Although this high burden of
HCV is gaining notoriety and modern treatment can
provide noticeable improvements in the health statuses of
most patients, many countries still lack HCV prevalence
data for high-risk groups. Epidemic patterns of HCV
infection related to injection drug use persist in Europe.
Understanding the risk factors for HCV infection among
prisoners may inform HCV prevention and treatment
intervention measures [2–5].
HCV prevalence is higher among prisoners than in the
general population [2]. Intravenous drug use (IDU) is
one of the major risk factors for HCV infection. The
prevalence of IDU in prisons is ranging from 2 to 38%
in Europe while the relevant percentage in the general
population is estimated at 0.3% in the European Union
and 0.2% in Australia. [6]. A metaanalysis showed that
people who inject drugs (PWID) were about 24 times
more likely to be infected with HCV than individuals in
the general population in Europe [7]. IDU [8] and tat-
tooing [9, 10] are the main risk behaviours for acquiring
HCV infection in prisons.
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Prisoners with human immunodeficiency virus (HIV)
are more likely to be infected with HCV probably
because of the similarity in the routes of transmission of
these blood-borne infections [1, 3]. According to recent
studies in Italian and US prisons, the HCV prevalence
was more than four times higher among HCV-HIV coin-
fected patients than among those not infected with HIV
(65.5–89.6% vs. 15.5–27.5%, respectively) [3, 11].
Another risk factor related to HCV infection is repeated
incarceration [12, 13], an association that may be con-
founded by low socioeconomic status, poor access to health
care, high-risk sexual behaviors and injection drug use [14].
In some studies HCV infection was observed more
frequently in female inmates than in males. [1]. In part
that may have been because the number of women in
prison has grown and women prisoners are more likely
than their male counterparts to have been incarcerated
for drug offences [15] and to have serious drug-related
health problems [16], including infectious diseases [17].
Direct-acting antivirals (DAAs) are relatively new and
expensive, but cost-effective when well utilised as inter-
ventions for chronic hepatitis C, and preliminary results
suggest that DAAs may eradicate HCV from the blood
(sustained virological response). The effect of long-term
treatment with DAA (hepatitis C morbidity and mortality)
is yet to be convincingly demonstrated [18]. Still, ribavirin
has been an integral component of treatment for hepatitis
C virus (HCV) infection, and the safety profile of ribavirin
is improved when co-administered with all-oral DAA
combinations in the absence of interferon [19]. Several
studies have shown that prisoners can be effectively
treated for HCV infection [20–22], although treatment is
administered less frequently to prisoners because of the
cost of treatment, treatment often exceeding average
prison stay combined with a lack of continuity of care,
and unawareness of the HCV infected status of the pris-
oners [1].
Most HCV infected people are unaware of their condi-
tion [23]. Prisons may be a good venue to detect many
of those cases. Although exact data are not available,
each year, up to one million people with undiagnosed
HCV infection may come into contact with the correc-
tional system in the United States [24]. Strategies of case
finding should be developed that are based on current
infections rates and feasibility.
The situation in Estonian prisons
The prison population in Estonia has stabilised at nearly
3000 individuals in recent years but the incarceration rate,
with 222 prisoners per 100,000 population, still remains
very high. According to the Council of Europe’s annual
penal statistics, the highest incarceration rates in Europe
are recorded in the former Soviet Union countries (439
per 100,000 population in the Russian Federation, 277 per
100,000 in Lithania, 274 per 100,000 in Georgia, 248 per
100,00 in Azerbaijan and 223 per 100,000 in Latvia) [25].
Needle and syringe exchange programmes (NSP) in
Estonia were launched in 1997. In addition to NSP,
condom distribution, different counselling services incl.
social, health, psychological, legal, experience counselling),
basic humanitarian aid, primary hygiene possibilities [26],
naloxone take-home program training (since 2013), and
motivation and referral to treatment/rehabilitation are
offered under harm reduction services in Estonia. From
2015, naloxone is available also in prisons [27]. In all
Estonian prisons, opioid substitution therapy (OST) in the
form of methadone treatment is provided. NSP are not
operating in Estonian prisons [28].
According to the Estonian Ministry of Justice, there were
3580 prisoners in Estonia’s four prisons during the period
between 1 January 2014 and 1 January 2015 (personal com-
munication with Asko Oruste, the information systems
manager with Estonian IT Support System). A study con-
ducted in Estonia in 2012–2013 found that, of all prisoners,
one-third had a history of drug use, 15.6% were infected
with HIV and, of those that were HIV-positive, 54.1% were
receiving antiretroviral therapy (ART) [28].
The implementation of the project “Improvement of Pre-
vention and Treatment of Infectious Diseases in Estonian
prisons” [29] targeting testing, treatment and infrastructure
buildings was a milestone in the diagnosis and care of HCV
in prisons [30]. Before that, HCV testing targeted only
prisoners considered at high risk for HCV (identified by
their drug use history or HIV status; “the old testing strat-
egy”) (personal communication with Maret Miljan from the
rehabilitation department of the Estonian prison depart-
ment,). Since the launch of the project in January 2014,
HCV tests have been offered for all newly incarcerated pris-
oners (“the new testing strategy”).
The aim of this study was to assess the prevalence of
HCV seropositivity and its related factors among newly
incarcerated prisoners and to describe the effects of treat-
ment of HCV infection in Estonian prisons.
Methods
This study was carried out from 1 January 2014 to 1 January
2015. The term ‘newly incarcerated prisoner’ is used for all
people, including adults and juveniles, detained during the
investigation of a crime, while awaiting trial, after convic-
tion, before sentencing and after sentencing, and incarcer-
ated in one of the four Estonian prisons.
Data and data sources
For this study we relied on the secondary data available in
the administrative and health databases of the Estonian
prison medical information system.
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Prison electronic patient database
The prison electronic patient database is designed for
prison healthcare and contains electronic health records.
For those tested for HCV, the following data were extracted
from prisoners’ health records: (i) HCV test result, (ii)
HCV genotype, (iii) age, (iv) gender, (v) HIV serostatus, (vi)
history of drug use (based on the International Classifica-
tion of Diseases codes F11-F16 or F18-F19), and (vii) HCV
treatment results. HCV in prisons is treated by prison in-
fectious diseases physicians who also make HCV-genotype
testing decisions.
For all samples collected in the prison medical informa-
tion system over the study period, HIV testing (Vironosti-
kaHIV Uniform II Ag/Ab, BioMerieux method), anti-HCV
antibodies testing (Siemens, A HCV200T KIT), and HCV
genotyping (The VERSANT® HCV Genotype 2.0 Assay)
were performed at Synlab Estonia (an accredited laboratory
following the requirements of ISO 15189 Medical
Laboratories).
Database of prisoners, detained persons, persons in custody
and probationers
Data on tattoos and previous incarceration were extracted
from the databases of prisoners, detained persons, persons
in custody and probationers (hereinafter referred to as the
prisoners’ register). The prisoners’ register is an electronic
database containing selected information on the details of
prison sentence as well as personal data. Information on
tattoos included in the register is based on inspection of
prisoners’ skin at prison entry.
Statistical analysis
Descriptive statistics are presented for categorical variables
(absolute number (n) and relative frequencies (%)) and
continuous variables (mean, standard deviation and range).
A chi-squared test was used to explore differences in cat-
egorical variables and the Wilcoxon rank sum test for age
comparisons between the HCV infected and non-infected
groups. Associations between antibodies to HCV (the out-
come of interest) and covariables were explored bivariably
and multivariably (by including all independent variables in
the model) by logistic regression analyses. Odds ratios (OR)
and adjusted OR (AOR) together with 95% confidence in-
tervals (CI) are presented. Associations between covariables
were also tested to assess the reliability of the multivariate
models (according to the possibility of multicollinearity).
The statistical software program SPSS version 16.0
(Chicago, Illinois, USA) was used.
Results
HCV and HIV diagnosis
Between 1 January 2014 and 1 January 2015, 1957 new
prisoners were admitted to the Estonian prison system. Of
those, 603 were already infected with HCV (based on data
from previous testing in prison). As per the new testing
strategy, the rest of the newly imprisoned individuals (n =
1242) were tested for HCV with the exception of 112 pris-
oners (26 prisoners declined testing and the reason for
not testing was unknown for the other 86).
The final sample consisted of 1845 newly incarcerated
prisoners with known HCV status. They had an average
age of 35 years (SD = 11.54, range 15–78). Of these pris-
oners, 94.4% were male (n = 1742), 58.1% had previously
used illicit drugs (n = 1034), 28.1% were tattooed (n =
519), and 68.9% had been previously incarcerated (n =
1272). The prevalence of HCV seropositivity was 56.3%
(n = 1038, 603 + 435) and the prevalence of HIV 25.5%
(95% CI 23.5–27.6%) (n = 469). One fifth (n = 379; 20.5,
95% CI 19.8–23.6%) of the newly incarcerated prisoners
had HCV-HIV co-infections. The majority (80.8, 95% CI
77.2–84.4%) of the HIV-positive prisoners were also
infected with HCV (Table 1).
The old testing strategy – high-risk based case finding
- would have identified only 37.7% (164/435) of the
HCV infected newly incarcerated prisoners.While com-
paring HCV infected and non-infected newly incarcer-
ated prisoners, we found that HCV-infected prisoners
tended to be slightly older, and were more likely to have
a tattoo (63.8% vs 36.2%, p < 0.001), to have a history of
drug use (76.6% vs 23.4%; p < 0.001), to be HIV-infected
(80% vs 19.2%, p < 0.001), and to have previously been
incarcerated (65.1% vs 4.9%, p < 0.001). There were no
gender differences in HCV seropositivity (Table 2).
After adjustment, history of drug use emerged as the
factor most strongly associated with HCV seropositivity
(AOR 6.51 95% CI 5.12–8.28). The risk of HCV sero-
positivity was also significantly higher among those who
were HIV-positive (AOR 2.56 95% CI 1.92–3.43) and
those previously incarcerated (AOR 3.16 95% CI 2.48–
4.04). The risk of HCV positivity increased with age.
While tattooing was associated with the HCV rates in
the bivariable analysis, this association was not found in
the multivariable analysis.
HCV genotypes
Of the 1038 prisoners who tested positive for HCV, 383
(36.9%) underwent HCV genotype testing. The main ge-
notypes identified were 3a (44.4%, n = 172) and 1b (35.2%,
n = 135). A further 17% (n = 65) had genotype 1a, and
2.6% prisoners (n = 10) had genotype 2. Only one prisoner
had HCV genotype 4.
HCV treatment
Between 1 January 2014 and 1 January 2015, all HCV cases,
25 prisoners (24 male and 1 female), received HCV treat-
ment (pegylated interferon (PEG-INF) and ribavirin). The
decision to treat was reached after an in-depth, individual-
ized process including informed consent and considering
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other factors such as co-morbid addiction and mental
illnesses. For patients with a history of drug use, a
program-based addiction treatment [31] was required to
initiate HCV treatment. Inmates who had a history of
depression or another psychiatric disorder were referred to
an on-site psychiatrist for evaluation. Prisoners with HCV
genotype 1b or with HIV infection were treated for
48 weeks, and those with genotypes 2 or 3 were treated for
24 weeks [32]. Individual treatment decisions were made by
prison infectious disease physicians based on whether the
expected length of stay was long enough to allow for the
completion of a treatment course (24 to 48 weeks). Clinical
indicators for treatment and funds available for the medica-
tions were also taken into consideration. Of those who
received HCV treatment, 21 (84%) had a history of drug
use (11 opiate users, 5 stimulant users and 5 users of mul-
tiple drugs including opiates), 5 (20%) were HIV infected,
none was hepatitis B infected, 24 (96%) had received hepa-
titis B vaccination before treatment.
None of the patients had previous experience with
interferon and ribavirin. The average age of treated
patients was 35.5 years (range 29–45). Fifteen of 25
(60%) treated patients underwent ultrasound-guided
liver biopsies. The Metavir scoring system was used to
classify fibrosis levels [33]. 11 (91.7%) of those biopsied
had no to mild fibrosis, 1 person had moderate (9%) and
3 (27.3%) had severe fibrosis of the liver. Of all the
patients treated, 15 (60%) were cured based on a nega-
tive HCV RNA test at the end of the treatment and 6
months after the treatment; 4 (16%) relapsed based on a
negative HCV RNA at the end of the treatment and
positive HCV RNA test 6 months after the treatment (3
patients with genotype 3a, one with 1b); 3 (12%) were
unresponsive to treatment based on an HCV RNA test
at 24 weeks of treatment (all with genotype 3a); 1 person
(4%) stopped treatment; and treatment outcome data
were missing for 2 (8%) of the patients as they had been
released from prison.
Table 2 Factors associated with hepatitis C infection among newly admitted prisoners in Estonia, 2014 to 2015, univariate and
multivariable logistic regression analyses (n = 1845)
Variable Bivariable analysis Multivariable analysis
OR c CIb (95%) Adjusted OR CI (95%)
Age 1.01 1.00–1.02*** 1.01 1.00–1.02***
Gender (female) 1.09 0.73–1.63 1.30 0.79–2.15
Tattoo (yes) 1.54 1.25–1.90*** 0.81 0.62–1.04
Drug use history (yes) 8.49 6.87–10.49*** 6.51 5.12–8.28***
HIVa infected (yes) 4.62 3.59–5.96*** 2.56 1.92–3.43***
Previous incarceration (yes) 3.2 2.61–3.93*** 3.16 2.48–4.04***
*** p-value < 0.01
Table 1 Factors associated with hepatitis C infection among newly incarcerated prisoners in Estonia, 2014 to 2015 (n = 1845)
Variable All N = 1845 HCV + b (n; %) HCV-c (n; %) p-value (HCV + vs HCV-)
Age (mean; SD) 34.1; 10.92 35.66; 11.49 34.11; 11.56 p < 0.001
Gender (male: n; %) 1742; 94.4% 978; 56.1% 764; 43.9% p = 0.675
Age group
15–20 107 36; 33.6% 71; 66.4%
21–30 620 330; 53.2% 290; 46.8%
31–40 494 304; 61.5% 190; 38.5%
41–50 304 177; 58.2% 127; 41.8%
51–60 183 103; 56.3% 80; 43.7%
61–70 30 25; 83.3% 5; 16.7%
71–78 4 3; 75% 1; 25%
Tattoo (yes: n; %) 519; 28.1% 331; 63.8% 188; 36.2% p < 0.001
Drug use history (yes: n; %) 1034; 56.2% 819; 76.6% 250; 23.4% p < 0.001
HIVa infected (n; %) 469; 25.5% 379; 80.8% 90; 19.2% p < 0.001
Previous incarceration (yes: n; %) 1271; 68.9% 827; 65.1% 444; 34.9% p < 0.001
aHIV: human immunodeficiency virus
bHCV+: Hepatitis C virus positive
cHCV-: Hepatitis C virus negative
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Discussion
To our knowledge, this is the first study focusing on HCV
prevalence and HCV treatment outcomes in the entire
prison population of a European country. The studies that
do exist are often restricted to individual prisons or sub-
groups of prisoners [2].
We found high HCV seropositivity rates (56%) among
newly imprisoned individuals in Estonia. HCV seropositiv-
ity among newly incarcerated and tested prisoners (with
either unknown HCV status or previous negative HCV
test) was 35%. These prevalence figures are consistent
with those from Italy (38%) [34] and Scotland (19%) [35],
where available data suggest that HCV is highly prevalent
among prisoners.
The risk factors for HCV seropositivity we observed
(drug use, previous incarceration, HIVstatus, age) are in
accordance with previous research [1, 2, 8, 14, 36]. Ac-
cording to previous studies in other countries, the main
risk factor associated with HCV infection in prison popu-
lations is IDU [1, 2, 8, 37]. In our study, the odds for being
HCV-positive were about three times higher among
HIV-positive than HIV-negative prisoners. HIV and HCV
share common routes of transmission, and are therefore
expected to some extent co-infect the same individuals.
Previous incarceration has been significantly associated
with HCV infection in studies from Australia, England,
and Wales [36–38]. Multiple incarcerations were also
found to be a risk factor for HCV seropositivity in our
study. The contribution of HCV transmission in prison
to the overall disease burden among PWID is difficult to
document owing to uncertainties regarding precise date
of infection and risk behaviours in the community (both
prior to and post-incarceration). The role of prisons as a
risk environment for the reinforcement, concentration
and amplification of infections such as HIV and HCV
has been suggested [39].
In our study, the seropositivity of HCV was higher
among those with tattoos. However, this association was
lost while adjusting for potential confounders. It is known
that tattooing is common in prisons and jails [10] and
prisoners who acquired their tattoos in prisons are more
likely to be HCV-infected [1, 12, 34]. The risks and
benefits of legal tattooing in prison should be discussed.
Evidence from studies on the relationship between tattoo-
ing and HCV transmission in prisons appears to be mixed.
Some studies report significant correlations [10, 36, 40]
while others do not [41].
We found the presence of hepatitis C antibodies in 12
individuals (0.6%) who were HIV negative and had no
records indicative of drug use. While we do not have data
on other HCV risk factors (such as history of blood trans-
fusion, high risk sexual behviour), all of the 12 prisoners
had tattoos. Eight of them had acquired their tattoos while
in prison during the Soviet era (personal communication
with prisoners). One might speculate that the traditions of
tattooing in prisons have changed (there appear to be
fewer tattoos among more recent prison populations and
drug using individuals).
Data on the relationship between HCV and gender in
prison populations is also conflicting. In some studies,
HCV infection was observed more frequently in incar-
cerated women than in incarcerated men. [1, 3]. Other
studies did not find the same result [42]. In our study,
after accounting for other risk factors, gender did not
emerge to be associated with HCV seropositivity.
Screening strategies based on risk factors have trad-
itionally failed to identify all patients at risk of infection,
leaving a sizable proportion of patients unaware of their
infection. We observed that a screening system for HCV
case finding relying only on known risk factors misses a
sizeable proportion of newly incarcerated individuals
with HCV infection. The all-inclusive HCV testing strat-
egy identified 37.7% more HCV infection cases among
the newly incarcerated than would have been detected
on the basis of known risk factors (drug use history,
HIV infected status) screening.
In our study, the main HCV genotypes were 3a (n = 172,
44%) and 1b (n = 135, 35.2%). HCV genotypes have
geographically distinct distributions. HCV genotype 1 and 3
infections are globally more prevalent than all other
genotypes. Those genotypes, more commonly found in
lower-income countries, account for a significant propor-
tion of HCV cases worldwide [43]. Meyer et al. found that
genotype 3 prevailed in prisoners from the independent
states of the former Soviet Union [44]. Tyczyno et al. com-
pared the HCV genotyping performed on Polish prisoners
and hospital patients, and found that HCV genotype 3 pre-
vailed in the prisoners (60.1%) and genotype 1 in patients at
large (79.6%). This distinction is most probably due to the
fact that genotype 3 is more frequent in PWID [45]. In
Estonia, the following distribution of genotypes was docu-
mented among hospital patients: genotype 1b was found in
32% of the patients, 3a was found in 20%, 2a in 12%, and
1a/b (double infection) in 28% [46]. Among the Estonian
prisoners tested for HCV genotypes nearly two decades
later, we were unable to replicate the finding of 1a/b double
infection occurrence.
The response to antiviral treatment in prisoners is similar
to that of the general population [1]. Our study observed a
60% sustained viral response among treated prisoners.
Importantly, this result does not differ from the treatment
response reported from the community (in a hospital
setting in Estonia) where a 60.3% sustained treatment
response was achieved [47]. This suggests that acceptable
HCV treatment outcomes can be achieved in prisons.
There are clear advantages to HCV treatment in prison
settings. In-prison, treatment provides the opportunity to
access population groups for whom treatment options may
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be limited after release. Treatment in prisons occurs in
controlled, directly observed settings, potentially achieving
increased compliance and monitoring for side effects and
complications [48, 49].
Our study has some strengths and limitations. A key
feature of our study is the all-inclusive testing strategy and
national coverage of the data collection. This is different
from other, similar studies [11, 12, 14] conducted in the
region because testing was offered and data were collected
from all new prisoners entering all Estonian prisons. How-
ever, given the nature of the data used, we were unable to
determine the frequency or duration of drug injection
and, particularly importantly, distinguish between inject-
ing and other types of drug use. Thus, some of the import-
ant details might have been lost. Importantly, we were
unable to assess the impact of other potential HCV risk
factors (such as sexual behaviour and previous blood
transfusions, or surgery).
Conclusions
Case finding for HCV infection in prisons, HCV treatment
and educational programmes to discourage high-risk
behaviours might help curtail the rise in HCV infection in
prison populations. Our study suggests that HCV treatment
in infected inmates is feasible and the results (sustained
viral response achievement) do not differ from that in the
community.
Reducing HCV prevalence among prisoners has the
potential to reduce the burden of disease in the general
public in the community. When developing HCV screen-
ing strategies in prisons, policy-makers should consider
the risk factors that we have highlighted in our study.
Our findings have several implications: they show that
(i) universal HCV testing at prisonentry has the potential
to increase the number of people who are aware of their
infection, (ii) there is a need to scale up comprehensive
HCV care to those infected. We believe that the results
of this study might be applicable to other countries in
the region that have witnessed injection drug use and
related HIV epidemics in the late 1990s and early 2000s.
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